Current therapies for Alzheimer’s disease (AD) primarily target tau and amyloid beta (Aβ) peptides and include inhibitors to reduce tau protein phosphorylation and BACE inhibitors to reduce Aβ levels. Aβ antibodies are also used to sequester free Aβ from plasma for clearance by the immune system. The development of effective AD therapies is very challenging and few compounds have shown significant benefits in clinical trials, primarily due to the lack of druggable targets and reliable biomarkers.

Translating Cognitive Decline in Mice

Hear how touchscreen testing is changing the way cognitive changes are measured.

Listen Now »

At Charles River, our scientists can guide you in the selection of the appropriate assay or disease model for every stage of the drug discovery process. Our extensive portfolio supports novel study designs and offers end-to-end validated in vitro services and in vivo models of pharmacology and toxicology. Our novel imaging modalities, behavioral tests and biomarker endpoint assays enable you to make effective decisions to help identify new therapies for Alzheimer’s disease.

Request information about AD capabilities »

We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our Alzheimer’s disease models.

You may also be interested in...


AD Guidebook

Learn best practices for the measurement, design, analysis and reporting of preclinical animal studies in Alzheimer's research and therapies.

Webinar Replays

Search our webinar archives to find additional trainings, educational presentations and resources related to Alzheimer's disease.

Featured Stories

From new models to expanded services, get the most up-to-date news.

Alzheimer’s disease experts reviewing papers

Blog Posts

Read what the Alzheimer’s disease experts are saying about everything from rodent models and genetic influences to promising testing methods and treatments.